The Medicare GLP-1 Bridge is a temporary CMS demonstration that, for the first time, covers GLP-1 drugs prescribed for obesity alone under Medicare Part D. It launched July 1, 2026 and runs through December 31, 2027, capping the beneficiary copay at $50 a month for Foundayo (orforglipron), Wegovy injection and tablets, and the Zepbound KwikPen.
Humana, which already runs the Limited Income Newly Eligible Transition program, acts as the single central processor, handling prior authorization, claims, and pharmacy payment. Claims must route through BIN 028918 and PCN MEDDGLP1BR rather than a beneficiary's normal Part D plan — a detail that left eligible seniors denied at the counter during the first week. KFF estimated 3.8 million beneficiaries qualify and projected federal cost between $1.3 billion at 10% participation and $10 billion at 75%, on a net payment near $195 a month per beneficiary after the copay. CMS Medicare Director Chris Klomp has said he expects early participation in the single-digit millions.
Stories here track the launch, operations, cost projections, and manufacturer participation. See #cms, #humana, #foundayo, and #prior-authorization.
Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.
A Medical Daily report on July 6 found that eligible Part D beneficiaries are walking away from pharmacy counters without their GLP-1 prescriptions five days after the Bridge launched July 1. The rejections stem from a technical routing problem: when a pharmacy submits the claim through a patient's normal Part D plan, it is automatically denied. The fix is to route the claim through Humana's central processor using BIN 028918 and PCN MEDDGLP1BR, a detail many patients and pharmacists were unprepared for.
KFF (formerly Kaiser Family Foundation) published cost-projection detail on the Medicare GLP-1 Bridge demonstration this week that goes beyond the 3.8 million eligibility headline into the fiscal outlay Medicare actually books. The math: Medicare's net drug payment runs $195 per beneficiary per month ($245 negotiated net drug price minus the $50 patient copay). At 10% participation of the 3.8 million eligible Part D enrollees, monthly refills across the 18-month program cost Medicare roughly $1.3 billion; at 25% participation, $3.3 billion; at 50% participation, $6.7 billion; at 75% participation, $10 billion. CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first with volume ramping through Q3 and Q4 2026, suggesting the middle of the KFF range as the most probable outcome. The Bridge operates outside the standard Part D risk pool, meaning Part D plan sponsors do not carry actuarial risk for these drugs; beneficiary spending under the Bridge does not count toward the Part D $2,100 annual out-of-pocket cap for 2026. The cost-projection frame is the piece analysts and Congressional staff will use to judge Bridge success over the next 18 months.
Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.
Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
KFF (formerly Kaiser Family Foundation) published an analysis estimating 3.8 million Medicare beneficiaries could have qualified for the Medicare GLP-1 Bridge in 2023 based on the three BMI-and-comorbidity eligibility tiers (BMI ≥35 no paired condition; BMI ≥30 with heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease). CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026 as prescriber and pharmacy familiarity grows. Centene confirmed participation in the Bridge program despite the parallel delay in its Medicare Advantage pilot. The Bridge operates outside standard Part D risk pools; Part D plan sponsors do not carry risk for eligible GLP-1 drugs under the Bridge. Net drug pricing runs $245/month with CMS covering $195 and the patient paying the $50 copay.
Becker's Payer Issues published a launch-day analysis titled '4 questions linger as CMS launches the Medicare GLP-1 Bridge' identifying operational uncertainties in the program even as the first prescriptions begin flowing. The four questions: (1) CMS could not confirm cost or enrollment projections on the launch call, leaving analyst modeling of program cost dependent on informal expectations from CMS Medicare Director Chris Klomp; (2) how quickly enrollment will build past Klomp's 'single-digit millions' framing given the manual prior-authorization workflow; (3) the absence of a formal appeals process within the Bridge itself (providers can resubmit eligibility forms repeatedly but there is no defined appeals track for denied prior authorizations); (4) whether manufacturer-negotiated pricing arrangements will hold at the $245 net price if utilization runs above expectations. The Bridge bypasses Part D sponsors entirely, in contrast to the voluntary Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model launching January 2027 in Part D, which required sponsors to sign on. The Bridge's central-processor architecture through Humana handles all payment and prior-authorization traffic outside the standard Part D benefit structure.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.
The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.